Xeris Pharmaceuticals Stock Market Value
| XERS Stock | USD 6.84 0.24 3.64% |
| Symbol | Xeris |
Xeris Pharmaceuticals Price To Book Ratio
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xeris Pharmaceuticals. If investors know Xeris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xeris Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Revenue Per Share | Quarterly Revenue Growth 0.488 | Return On Assets | Return On Equity |
The market value of Xeris Pharmaceuticals is measured differently than its book value, which is the value of Xeris that is recorded on the company's balance sheet. Investors also form their own opinion of Xeris Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Xeris Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xeris Pharmaceuticals' market value can be influenced by many factors that don't directly affect Xeris Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xeris Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xeris Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xeris Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Xeris Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Xeris Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Xeris Pharmaceuticals.
| 05/12/2025 |
| 08/10/2025 |
If you would invest 0.00 in Xeris Pharmaceuticals on May 12, 2025 and sell it all today you would earn a total of 0.00 from holding Xeris Pharmaceuticals or generate 0.0% return on investment in Xeris Pharmaceuticals over 90 days. Xeris Pharmaceuticals is related to or competes with Protalix Biotherapeutics, Seres Therapeutics, Cidara Therapeutics, Immunitybio, Mereo BioPharma, Terns Pharmaceuticals, and PDS Biotechnology. Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for pat... More
Xeris Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Xeris Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Xeris Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.61 | |||
| Information Ratio | 0.1569 | |||
| Maximum Drawdown | 23.1 | |||
| Value At Risk | (3.74) | |||
| Potential Upside | 6.46 |
Xeris Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Xeris Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Xeris Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Xeris Pharmaceuticals historical prices to predict the future Xeris Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.1528 | |||
| Jensen Alpha | 0.726 | |||
| Total Risk Alpha | 0.166 | |||
| Sortino Ratio | 0.2556 | |||
| Treynor Ratio | 1.64 |
Xeris Pharmaceuticals Backtested Returns
Xeris Pharmaceuticals appears to be moderately volatile, given 3 months investment horizon. Xeris Pharmaceuticals shows Sharpe Ratio of 0.15, which attests that the company had a 0.15 % return per unit of risk over the last 3 months. By examining Xeris Pharmaceuticals' technical indicators, you can evaluate if the expected return of 0.58% is justified by implied risk. Please utilize Xeris Pharmaceuticals' Downside Deviation of 2.61, market risk adjusted performance of 1.65, and Mean Deviation of 2.7 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Xeris Pharmaceuticals holds a performance score of 11. The firm maintains a market beta of 0.48, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Xeris Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Xeris Pharmaceuticals is expected to be smaller as well. Please check Xeris Pharmaceuticals' semi variance, as well as the relationship between the rate of daily change and relative strength index , to make a quick decision on whether Xeris Pharmaceuticals' historical returns will revert.
Auto-correlation | -0.12 |
Insignificant reverse predictability
Xeris Pharmaceuticals has insignificant reverse predictability. Overlapping area represents the amount of predictability between Xeris Pharmaceuticals time series from 12th of May 2025 to 26th of June 2025 and 26th of June 2025 to 10th of August 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Xeris Pharmaceuticals price movement. The serial correlation of -0.12 indicates that less than 12.0% of current Xeris Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.12 | |
| Spearman Rank Test | -0.16 | |
| Residual Average | 0.0 | |
| Price Variance | 0.3 |
Xeris Pharmaceuticals lagged returns against current returns
Autocorrelation, which is Xeris Pharmaceuticals stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Xeris Pharmaceuticals' stock expected returns. We can calculate the autocorrelation of Xeris Pharmaceuticals returns to help us make a trade decision. For example, suppose you find that Xeris Pharmaceuticals has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Xeris Pharmaceuticals regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Xeris Pharmaceuticals stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Xeris Pharmaceuticals stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Xeris Pharmaceuticals stock over time.
Current vs Lagged Prices |
| Timeline |
Xeris Pharmaceuticals Lagged Returns
When evaluating Xeris Pharmaceuticals' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Xeris Pharmaceuticals stock have on its future price. Xeris Pharmaceuticals autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Xeris Pharmaceuticals autocorrelation shows the relationship between Xeris Pharmaceuticals stock current value and its past values and can show if there is a momentum factor associated with investing in Xeris Pharmaceuticals.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.